Antios Therapeutics

OverviewSuggest Edit

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. The Company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.

TypePrivate
Founded2018
HQAtlanta, GA, US
Websiteantiostherapeutics.com

Latest Updates

Employees (est.) (Nov 2021)19
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Antios Therapeutics

Greg Mayes

Greg Mayes

Chief Executive Officer
Arbutus Biopharma

Arbutus Biopharma

Former Chief Operating Officer
Doug Mayers

Doug Mayers

Chief Medical Officer
Tamra Adams

Tamra Adams

Chief Financial Officer
Katie Laessig

Katie Laessig

Senior Vice President, Global Regulatory Affairs
Karen Fusaro

Karen Fusaro

Senior Vice President, Clinical Operations
Show more

Antios Therapeutics Office Locations

Antios Therapeutics has an office in Atlanta
Atlanta, GA, US (HQ)
P.O. Box 12260
Show all (1)

Antios Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Antios Therapeutics total Funding

$25 m

Antios Therapeutics latest funding size

$25 m

Time since last funding

3 years ago

Antios Therapeutics investors

Antios Therapeutics's latest funding round in November 2018 was reported to be $25 m. In total, Antios Therapeutics has raised $25 m
Show all financial metrics

Antios Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Antios Therapeutics Online and Social Media Presence

Embed Graph

Antios Therapeutics News and Updates

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

MENDHAM, N.J. and ROME, Nov. 15, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and...

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of a $75 million Series B-1 financing. The...

Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in...

Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conference

MENDHAM, N.J., Oct. 7, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced that Chief Executive Officer, Gregory Mayes and Chief Medical...

Antios Therapeutics Announces Presentation at ICE-HBV Toronto Annual Symposium in Conjunction with the International HBV Meeting

MENDHAM, N.J., Sept. 22, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios") today announced that Douglas Mayers, M.D., Chief Medical Officer and Co-Founder of Antios, will be giving a presentation on ATI-2173, an investigational liver-targeting Active Site Polymerase Inhibitor...

Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs

ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Catherine Coffey Ross as Vice President, Medical Affairs. Ms. Coffey Ross’ appointment was driven by the significant progress of the Company’s lead asset, ATI-2173, a unique Active Si…
Show more

Antios Therapeutics Frequently Asked Questions

  • When was Antios Therapeutics founded?

    Antios Therapeutics was founded in 2018.

  • Who are Antios Therapeutics key executives?

    Antios Therapeutics's key executives are Greg Mayes, Arbutus Biopharma and Doug Mayers.

  • How many employees does Antios Therapeutics have?

    Antios Therapeutics has 19 employees.

  • Who are Antios Therapeutics competitors?

    Competitors of Antios Therapeutics include Dexa Medica, Insud Pharma and Mochida Pharmaceutical.

  • Where is Antios Therapeutics headquarters?

    Antios Therapeutics headquarters is located at P.O. Box 12260, Atlanta.

  • Where are Antios Therapeutics offices?

    Antios Therapeutics has an office in Atlanta.

  • How many offices does Antios Therapeutics have?

    Antios Therapeutics has 1 office.